Types segmentation classifies Hyperbilirubinemia Treatment by therapeutic modality, revealing distinct cost structures and adoption curves. Phototherapy remains the primary non‑invasive modality, accounting for roughly 45 % of treatment spend; its reliance on blue‑light devices and relatively low per‑session cost makes it the first‑line option for most neonatal cases. Exchange transfusion, an invasive procedure used when bilirubin exceeds phototherapy thresholds, contributes about 20 % of market value due to higher resource utilization, intensive care requirements, and limited procedural frequency. Pharmacologic agents constitute the next largest slice at 25 %, encompassing enzyme inducers such as phenobarbital, enzyme inhibitors like metalloporphyrins, and newer RNA‑based therapies; these sub‑categories differ in mechanism, dosing complexity, and reimbursement pathways, driving heterogeneous pricing. Surgical interventions, including biliary drainage or liver transplantation for refractory genetic forms, represent the remaining 10 % and are characterized by high capital expenditure and specialized clinical expertise. This market taxonomy underscores how each treatment type shapes overall spend, with clinical severity, patient age, and health‑system capacity dictating the relative weight of each segment.
